ICG

Rounds

• M Mediar TherapeuticsDevelops first-in-class antibody treatments for fibrosis $76MSeries B · 7 Jan
• W WugenClinical-stage biotech developing donor-derived gene-edited CAR-T therapy for T-cell leukemia and lymphoma $115M4 Sept

No round matches these filters.

Often invests with

• Abingworth1
• Aisling Capital Management1
• Alexandria Venture Investments1
• Amplitude Ventures1
• Asahi Kasei Pharma Ventures1
• Fidelity Management & Research1
• Lightchain Capital1
• Longwood Fund1